PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Nature publishes results of gene therapy treatment in phase 1/2 beta-thalassemia study

Successful clinical response achieved in beta-thalassemia patient with single treatment of bluebird bio's lentiviral gene therapy

2010-09-15
(Press-News.org) Cambridge, Mass., September 15, 2010 – bluebird bio (formerly Genetix Pharmaceuticals Inc.) an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced publication in the journal Nature of its promising Phase 1/2 data highlighting positive results of LentiGlobin™ gene therapy treatment in a young adult with severe beta-thalassemia, a blood disorder that is one of the most frequent inherited diseases.

The patient, who had been transfusion dependent since early childhood, has become transfusion independent for the past 21 months – more than two years after treatment with the LentiGlobin vector. The study also identified a subset of cells with the corrected beta-globin gene that overexpressed a truncated form of a gene called HMGA2. The patient has not experienced any adverse events. The data show that while early on, the HMGA2 clone was a significant portion of the corrected cells, the clone levels had declined at the time the paper was prepared, and further follow up indicates the decline is continuing.

"Although based on the first treated patient, we believe these results are impressive and illustrate for the first time the significant potential for treatment of beta hemoglobinopathies using lentiviral beta-globin gene transfer in the context of autologous stem cell transplant," said Philippe Leboulch, M.D., senior author of the study and head of the Institute of Emerging Diseases and Innovative Therapies of CEA and INSERM; professor of medicine, University of Paris; and visiting professor, Harvard Medical School. "For beta-thalassemia, we have worked intensely for almost 20 years to design, develop and manufacture LentiGlobin to provide a sustained high level hemoglobin production, resulting in a major clinical benefit. It has been very rewarding to follow this patient as his life has dramatically improved since receiving our treatment."

"For the first time, a patient with severe beta-thalassemia is living without the need for transfusions over a sustained period of time," said Marina Cavazzana-Calvo, M.D., first co-author of the study and professor of hematology, University of Paris and chief of Cell and Gene Therapy Department, Necker-Enfants Malades Hospital in Paris. Salima Hacein-Bey-Abina, Ph.D., professor of immunology, University of Paris, added, "These results are not only important due to the tremendous medical need that exists for thalassemia patients around the world, but also represents a significant step forward for the field of autologous stem cell therapy as an emerging therapeutic modality."

Dr. Françoise Bernaudin, the clinical hematologist who has followed this patient since early childhood, said, "It is wonderful to see that this young man is for now free of transfusions and injections for iron chelation. He is happy to have a normal life back, and for the first time has a full-time job as a cook in a main restaurant in Paris. We are now even able to bleed him regularly to help remove toxic iron that had accumulated over the years because of blood transfusions."

The paper, titled "Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassemia," is available in the online publication of Nature at www.nature.com.

"We believe the human findings in beta-thalassemia, as well as the recently published data in Science on two patients with childhood cerebral adrenoleukodystrophy (CCALD), highlight the significant opportunity for bluebird bio's gene therapy platform to help patients with severe genetic disorders," said Nick Leschly, president and CEO of bluebird bio. "We are committed to building a world-class company in gene therapy led by outstanding people as we move aggressively forward with multiple clinical studies, including our ongoing clinical trials for the development of LentiGlobin for beta-thalassemia and our product for CCALD."

INFORMATION: About Beta-Thalassemia

Thalassemias are inherited blood disorders that cause the body to have an inadequate amount of hemoglobin, the protein in red blood cells that carries oxygen. Beta-thalassemia is named for defects in production of the beta-globin chain of hemoglobin and mostly affects people of Mediterranean, Middle Eastern, South Asian, Southeast Asian and Chinese descent. Approximately 60,000 children are diagnosed with the disease each year throughout the world. The severe form of beta-thalassemia, also known as thalassemia major or Cooley's anemia, occurs when both beta-globin genes (one from each parent) are mutated. In beta E /beta 0-thalassemia, as in the study's treated patient, one of the mutated genes is completely silent while the other expresses low levels of a mutated protein (beta E). This form is especially common in Southeast Asian countries and their diasporas. Immigration patterns have made this form the most frequent in the West coast of the United States. Patients typically require monthly supportive red blood cell transfusions to treat their severe anemia for life. Unfortunately, over time these transfusions lead to severe iron overload that causes serious damage to many organs. Patients must regularly take chelating drugs to remove the excess iron to stay alive. The other option – allogeneic stem cell transplantation – carries a significant risk of morbidity and mortality.

About LentiGlobin®

bluebird bio's LentiGlobin introduces a fully functional human beta-globin gene, under the control of the beta-globin enhancer and locus control region, into the patient's own hematopoietic stem cells in the bone marrow. bluebird bio is conducting a Phase 1/2 trial examining the feasibility, safety and efficacy of LentiGlobin in the treatment of beta-thalassemia and sickle cell anemia. By adding a single transduction step to the routine practice of autologous bone-marrow transplantation, LentiGlobin may extend the benefit of bone-marrow transplantation to the 75 percent of patients lacking matched sibling donors. Additionally, not only would autologous bone marrow transplantation avoid the mortality and morbidity associated with graft-versus-host disease and immune suppression, but a one-time gene transfer could replace lifetime monthly transfusions and daily overnight iron chelation therapy associated with thalassemia.

About bluebird bio

bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bio's product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The company's novel approach uses stem cells harvested from the patient's bone marrow into which a healthy version of the disease causing gene is inserted. After being grown in culture, those cells are given back to the patient. bluebird bio's approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential complications associated with donor cell transplantation and presenting a one-time transformative therapy. bluebird bio has two later stage clinical products in development for childhood cerebral adrenoleukodystrophy (CCALD) and beta-thalassemia/sickle cell anemia. Led by a world-class team, bluebird bio is privately held and backed by top-tier life sciences investors, including Third Rock Ventures, TVM Capital, Forbion Capital Partners, Easton Capital and Genzyme Ventures. Its operations are located in Cambridge, Mass. and Paris, France. For more information, please visit www.bluebirdbio.com



ELSE PRESS RELEASES FROM THIS DATE:

King's College London reveals promising techniques for extending the life of an organ transplant

2010-09-15
Experts from the Medical Research Council (MRC) Centre for Transplantation at King's College London, based at Guy's Hospital, have revealed exciting new scientific developments for people with an organ transplant, intended to help prevent rejection of the new organ and extend its life. Although organ transplantation has been taking place for over 50 years, there are a number of significant challenges, such as a shortage of donor organs, maintaining the quality of an organ in transit, and the risk of organ rejection both immediately after transplant and in the following ...

Mount Sinai researchers develop database to help accelerate drug discovery

2010-09-15
Researchers from Mount Sinai School of Medicine have developed a new computational method that will help streamline the analysis of gene expression experiments and provide scientists with a better mechanistic understanding of the differences between diseased and normal cells. The new database and software, called ChIP Enrichment Analysis (ChEA), will revolutionize how researchers identify drug targets and biomarkers. Researchers can find the tool online at http://amp.pharm.mssm.edu/lib/chea.jsp. The data are published in the September 15th issue of Bioinformatics. Until ...

Discovery highlights promise of new immune system-based therapies

2010-09-15
BOSTON--A new focus on the immune system's ability to both unleash and restrain its attack on disease has led Dana-Farber Cancer Institute scientists to identify cells in mice that prevent the immune system from attacking the animals' own cells, protecting them from autoimmune diseases such as multiple sclerosis, type 1 diabetes, and lupus. The discovery, reported online on Sept. 16 by the journal Nature, may give scientists an effective way of operating the immune system's internal "control panel," leading to improved therapies for a variety of diseases – from vaccines ...

Home's electrical wiring acts as antenna to receive low-power sensor data

Homes electrical wiring acts as antenna to receive low-power sensor data
2010-09-15
If these walls had ears, they might tell a homeowner some interesting things. Like when water is dripping into an attic crawl space, or where an open window is letting hot air escape during winter. The walls do have ears, thanks to a device that uses a home's electrical wiring as a giant antenna. Sensors developed by researchers at the University of Washington and the Georgia Institute of Technology use residential wiring to transmit information to and from almost anywhere in the home, allowing for wireless sensors that run for decades on a single watch battery. The technology, ...

Robotic catheter could improve treatment of heart condition

Robotic catheter could improve treatment of heart condition
2010-09-15
VIDEO: NC State's Dr. Greg Buckner has developed a robotic catheter that is significantly more maneuverable than existing devices, which could lead to reduced operating times for patients undergoing heart surgery... Click here for more information. Atrial fibrillation is a heart disorder that affects more than two million Americans, and is considered a key contributor to blood clots and stroke. Now researchers from North Carolina State University are developing a new ...

Employee with higher level of emotional intelligence is more dedicated and satisfied at work

2010-09-15
Employees with a high level of emotional intelligence are more dedicated and satisfied at work, compared to other employees. This has been shown in a new study from the University of Haifa. "This study has shown that employees with a higher level of emotional intelligence are assets to their organization. I believe it will not be long before emotional intelligence is incorporated in employee screening and training processes and in employee assessment and promotion decisions" stated Dr. Galit Meisler, who conducted the research. The study, which Dr. Meisler carried out ...

Gene network reveals link between fats and heart disease signs

Gene network reveals link between fats and heart disease signs
2010-09-15
A gene network behind hardening of the arteries and coronary heart disease has been identified by a team of scientists from Australia, Europe and the United Kingdom. Their findings expose potential targets for the treatment of heart disease. Dr Michael Inouye, a postdoctoral fellow at the Walter and Eliza Hall Institute in Melbourne, Australia, began the study at the Wellcome Trust Sanger Institute in the UK and completed it earlier this year at the Walter and Eliza Hall Institute. Researchers from Finland's National Institute for Health and Welfare, the University of ...

Study into the booby traps of breastfeeding in the UK

2010-09-15
Australian researchers are embarking on a study of mums in the United Kingdom to discover if "guilt-tripping women" into breastfeeding is effective in persuading them to opt for breast over bottle. Queensland University of Technology (QUT) is a recognised leader in breastfeeding research and has already undertaken a study in Australia and the US. Lead researcher Joy Parkinson, from QUT's School of Advertising Marketing and Public Relations, said women were often made to feel guilty for not breastfeeding their children when in fact a more supportive approach might be ...

Eating broccoli could guard against arthritis

2010-09-15
Scientists at the University of East Anglia (UEA) are launching a groundbreaking new project to investigate the benefits of broccoli in the fight against osteoarthritis. Initial laboratory research at UEA has found that a compound in broccoli called sulforaphane blocks the enzymes that cause joint destruction in osteoarthritis – the most common form of arthritis. Broccoli has previously been associated with reduced cancer risk but this is the first major study into its effects on joint health. With funding from both Arthritis Research UK and the Diet and Health ...

Urgent steps needed to tackle inadequate support for women with secondary breast cancer

2010-09-15
The support provided for women with secondary breast cancer is inadequate and urgent steps are needed to provide better services for patients with this progressive incurable disease, which kills half a million women worldwide every year. Those are the key recommendations to emerge from a trio of papers in the September issue of the European Journal of Cancer Care. Fifty-seven per cent of breast care nurses who took part in a UK survey for Breast Cancer Care told researchers that they felt there was inadequate provision for women whose cancer has spread to other organs, ...

LAST 30 PRESS RELEASES:

2024 Joseph A. Johnson Award Goes to Johns Hopkins University Assistant Professor Danielle Speller

Slow editing of protein blueprints leads to cell death

Industrial air pollution triggers ice formation in clouds, reducing cloud cover and boosting snowfall

Emerging alternatives to reduce animal testing show promise

Presenting Evo – a model for decoding and designing genetic sequences

Global plastic waste set to double by 2050, but new study offers blueprint for significant reductions

Industrial snow: Factories trigger local snowfall by freezing clouds

Backyard birds learn from their new neighbors when moving house

New study in Science finds that just four global policies could eliminate more than 90% of plastic waste and 30% of linked carbon emissions by 2050

Breakthrough in capturing 'hot' CO2 from industrial exhaust

New discovery enables gene therapy for muscular dystrophies, other disorders

Anti-anxiety and hallucination-like effects of psychedelics mediated by distinct neural circuits

How do microbiomes influence the study of life?

Plant roots change their growth pattern during ‘puberty’

Study outlines key role of national and EU policy to control emissions from German hydrogen economy

Beloved Disney classics convey an idealized image of fatherhood

Sensitive ceramics for soft robotics

Trends in hospitalizations and liver transplants associated with alcohol-induced liver disease

Spinal cord stimulation vs medical management for chronic back and leg pain

Engineered receptors help the immune system home in on cancer

How conflicting memories of sex and starvation compete to drive behavior

Scientists discover ‘entirely unanticipated’ role of protein netrin1 in spinal cord development

Novel SOURCE study examining development of early COPD in ages 30 to 55

NRL completes development of robotics capable of servicing satellites, enabling resilience for the U.S. space infrastructure

Clinical trial shows positive results for potential treatment to combat a challenging rare disease

New research shows relationship between heart shape and risk of cardiovascular disease

Increase in crisis coverage, but not the number of crisis news events

New study provides first evidence of African children with severe malaria experiencing partial resistance to world’s most powerful malaria drug

Texting abbreviations makes senders seem insincere, study finds

Living microbes discovered in Earth’s driest desert

[Press-News.org] Nature publishes results of gene therapy treatment in phase 1/2 beta-thalassemia study
Successful clinical response achieved in beta-thalassemia patient with single treatment of bluebird bio's lentiviral gene therapy